These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 39156484)
1. The Role of Plasma Trough Concentration of Voriconazole and Voriconazole N-Oxide in Its Hepatotoxicity in Adult Patients. Cheng L; You X; Wang X; Yu M; Jia C Drug Des Devel Ther; 2024; 18():3617-3628. PubMed ID: 39156484 [TBL] [Abstract][Full Text] [Related]
2. Factors influencing plasma concentration of voriconazole and voriconazole- N-oxide in younger adult and elderly patients. Cheng L; Liang Z; Liu F; Lin L; Zhang J; Xie L; Yu M; Sun F Front Pharmacol; 2023; 14():1126580. PubMed ID: 36860301 [No Abstract] [Full Text] [Related]
3. Inflammation Affects Liver Function and the Metabolism of Voriconazole to Voriconazole-N-Oxide in Adult and Elderly Patients. Liang Z; Yu M; Liu Z; Liu F; Jia C; Xiong L; Dai Q; Qin S; Cheng L; Sun F Front Pharmacol; 2022; 13():835871. PubMed ID: 35462904 [No Abstract] [Full Text] [Related]
4. Hypokalemia and Hyponatremia in Adult Patients Receiving Voriconazole Therapeutic Drug Monitoring. Cheng L; Liu Z; Yu M; Lin L; Xiong L; Dai Q J Clin Pharmacol; 2024 Apr; 64(4):461-468. PubMed ID: 37910022 [TBL] [Abstract][Full Text] [Related]
5. Correlation of CYP2C19 genotype with plasma voriconazole exposure in South-western Chinese Han patients with invasive fungal infections. Miao Q; Tang JT; van Gelder T; Li YM; Bai YJ; Zou YG; Wang LL; Shi YY Medicine (Baltimore); 2019 Jan; 98(3):e14137. PubMed ID: 30653146 [TBL] [Abstract][Full Text] [Related]
6. Risk Factors for Voriconazole-Associated Hepatotoxicity in Patients in the Intensive Care Unit. Wang Y; Wang T; Xie J; Yang Q; Zheng X; Dong W; Xing J; Wang X; Dong Y Pharmacotherapy; 2016 Jul; 36(7):757-65. PubMed ID: 27284960 [TBL] [Abstract][Full Text] [Related]
7. Voriconazole trough concentration and hepatotoxicity in patients with low serum albumin . Hirata A; Noto K; Ota R; Yokoyama S; Hosomi K; Takada M; Matsuoka H Int J Clin Pharmacol Ther; 2019 Mar; 57(3):135-143. PubMed ID: 30686290 [TBL] [Abstract][Full Text] [Related]
8. The Influence of Proinflammatory Cytokines on Voriconazole Trough Concentration in Patients With Different Forms of Hematologic Disorders. Mafuru M; Wu S; He S; Lu X; Huang J; Jiang H J Clin Pharmacol; 2019 Oct; 59(10):1340-1350. PubMed ID: 30997931 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic drug monitoring and safety of voriconazole in elderly patients. Cheng L; Xiang R; Liu F; Li Y; Chen H; Yao P; Sun F; Xia P Int Immunopharmacol; 2020 Jan; 78():106078. PubMed ID: 31830620 [TBL] [Abstract][Full Text] [Related]
10. Moderate correlation between systemic IL-6 responses and CRP with trough concentrations of voriconazole. Vreugdenhil B; van der Velden WJFM; Feuth T; Kox M; Pickkers P; van de Veerdonk FL; Blijlevens NMA; Brüggemann RJM Br J Clin Pharmacol; 2018 Sep; 84(9):1980-1988. PubMed ID: 29744898 [TBL] [Abstract][Full Text] [Related]
11. Association of procalcitonin with voriconazole concentrations: a retrospective cohort study. Zhou JX; Xiong CL; Chang ZS; Yin YC; Su KP; Zhang JH; Wu JC; Sun B BMC Infect Dis; 2024 Sep; 24(1):952. PubMed ID: 39256640 [TBL] [Abstract][Full Text] [Related]
12. Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity. Dolton MJ; McLachlan AJ Int J Antimicrob Agents; 2014 Sep; 44(3):183-93. PubMed ID: 25106074 [TBL] [Abstract][Full Text] [Related]
13. Development of a therapeutic drug-monitoring algorithm for outpatients receiving voriconazole: A multicentre retrospective study. Kato H; Umemura T; Hagihara M; Shiota A; Asai N; Hamada Y; Mikamo H; Iwamoto T Br J Clin Pharmacol; 2024 May; 90(5):1222-1230. PubMed ID: 38320604 [TBL] [Abstract][Full Text] [Related]
14. Metabolomics Investigation of Voriconazole-Induced Hepatotoxicity in Mice. Wu SL; Wei TY; Lin SW; Su KY; Kuo CH Chem Res Toxicol; 2019 Sep; 32(9):1840-1849. PubMed ID: 31411454 [TBL] [Abstract][Full Text] [Related]
15. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections. Lamoureux F; Duflot T; Woillard JB; Metsu D; Pereira T; Compagnon P; Morisse-Pradier H; El Kholy M; Thiberville L; Stojanova J; Thuillez C Int J Antimicrob Agents; 2016 Feb; 47(2):124-31. PubMed ID: 26775563 [TBL] [Abstract][Full Text] [Related]
16. Association of Voriconazole Trough Plasma Concentration with Efficacy and Incidence of Hepatotoxicity in Iranian Patients with Hematological Malignancies. Taghvaye-Masoumi H; Hadjibabaie M; Ghadimi M; Zarif-Yeganeh M; Vaezi M; Ghavamzadeh A Iran J Pharm Res; 2021; 20(1):62-71. PubMed ID: 34400941 [TBL] [Abstract][Full Text] [Related]
17. Effect of CYP2C19 polymorphism on the plasma voriconazole concentration and voriconazole-to-voriconazole-N-oxide concentration ratio in elderly patients. Shang S; Cheng L; Li X; Xiang R; Yu M; Xiong L; Chen Y Mycoses; 2020 Nov; 63(11):1181-1190. PubMed ID: 32416606 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic drug monitoring of voriconazole in Japanese patients: analysis based on clinical practice data. Matsumoto K; Abematsu K; Shigemi A; Kanazawa N; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y J Chemother; 2016 Jun; 28(3):198-202. PubMed ID: 26187373 [TBL] [Abstract][Full Text] [Related]
19. Variability of voriconazole concentrations in patients with hematopoietic stem cell transplantation and hematological malignancies: influence of loading dose, procalcitonin, and pregnane X receptor polymorphisms. Zeng G; Wang L; Shi L; Li H; Zhu M; Luo J; Zhang Z Eur J Clin Pharmacol; 2020 Apr; 76(4):515-523. PubMed ID: 31932875 [TBL] [Abstract][Full Text] [Related]
20. Metabolomics analysis of plasma reveals voriconazole-induced hepatotoxicity is associated with oxidative stress. Wu SL; Cheng CN; Wang CC; Lin SW; Kuo CH Toxicol Appl Pharmacol; 2020 Sep; 403():115157. PubMed ID: 32717240 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]